A targeted therapy for EGFR-mutated advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing a new targeted pill for people with EGFR-positive non-small cell lung cancer. It's designed for those whose cancer has grown after other treatments, and it works by blocking a specific protein that helps the cancer grow.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been told that your lung cancer has an EGFR change that is known to respond to targeted treatment.
- You have had at least one previous treatment for your lung cancer.
- You are in generally good health overall (able to be up and about).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral pill (DZD9008) that targets a specific genetic change in lung cancer called EGFR. If you have this mutation, the drug may shrink your tumor or slow its growth, especially if other treatments have stopped working or caused side effects.
This trial tests a new combination of two oral targeted drugs for people with advanced non-small cell lung cancer that has an EGFR mutation. It may help if you have already been treated with a third-generation EGFR pill or if you are starting treatment for the first time.
This trial tests a new combination treatment for people with advanced non-small cell lung cancer that has an EGFR mutation. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests an oral drug called DZD6008 for people with advanced non-small cell lung cancer (NSCLC) that has certain EGFR mutations. It may be an option for those who have tried other EGFR treatments or are new to treatment.
This study tests an oral pill (BPI-361175) for people with advanced non-small cell lung cancer that has specific EGFR mutations, especially when standard EGFR-targeted treatments are no longer working. The goal is to see if it can shrink tumors or slow growth.
Hear when a new Nonsmall-cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.